This suggests that the administration of drugs that promote T cell trafficking to tumors before anti-PD-1/PD-L1 therapy may improve the clinical outcome for patients with an insufficient density of pre-existing tumor-infiltrating T cells. Here, PDCD1 is linked to neoplasm.